Validcare and Farmacon Global have announced a strategic partnership to enhance clinical trial execution. According to Validcare’s CEO Patrick McCarthy, this collaboration will “redefine clinical trial success from patient-centric design through database lock.”
The Validcare platform supports site-based, hybrid, and decentralized clinical trials while establishing key performance indicators to measure study success.
Sara Tylosky, CEO of Farmacon Global, emphasized the partnership’s value: “Partnering with Validcare allows our sponsors to quickly identify and implement ROI generating activities like increased patient enrollment.”
Farmacon Global specializes in accelerating clinical trials in emerging markets, particularly Latin America, with expertise in rare disease, cancer, immunology, and infectious disease research. The partnership enables the organization to offer enhanced data integrity through electronic case report forms, e-diaries, and real-world evidence applications.
McCarthy noted that together, both organizations will “provide proven processes, tools and technology to overcome the obstacles that typically cause clinical trial delays and failures,” with the goal of executing studies on time and within budget.
About Farmacon Global
A strategic contract research organization offering medical consulting solutions, operating primarily across Latin America and emerging markets.